Zoetis Inc. (ZTS) Holdings Trimmed by Banque Pictet & Cie SA
Banque Pictet & Cie SA lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 8.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,907 shares of the company’s stock after selling 4,000 shares during the quarter. Banque Pictet & Cie SA’s holdings in Zoetis were worth $2,672,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of ZTS. Northwestern Mutual Wealth Management Co. grew its holdings in Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares in the last quarter. Harfst & Associates Inc. grew its holdings in shares of Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Zoetis during the second quarter worth about $119,000. Peddock Capital Advisors LLC purchased a new position in shares of Zoetis during the second quarter worth about $140,000. Finally, Parallel Advisors LLC grew its holdings in shares of Zoetis by 41.1% during the second quarter. Parallel Advisors LLC now owns 2,263 shares of the company’s stock worth $141,000 after purchasing an additional 659 shares in the last quarter. 92.44% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently commented on ZTS shares. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Cantor Fitzgerald set a $75.00 price objective on Zoetis and gave the stock a “buy” rating in a report on Monday, August 14th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. BidaskClub raised Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Finally, Deutsche Bank AG lowered Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $67.65.
Shares of Zoetis Inc. (NYSE:ZTS) traded up $0.38 on Friday, reaching $70.79. The company’s stock had a trading volume of 2,337,803 shares, compared to its average volume of 2,995,809. The stock has a market capitalization of $34,495.12, a price-to-earnings ratio of 32.47, a P/E/G ratio of 2.07 and a beta of 1.02. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis Inc. has a 1-year low of $48.55 and a 1-year high of $71.12.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the previous year, the company posted $0.52 earnings per share. The business’s revenue was up 8.5% on a year-over-year basis. equities research analysts anticipate that Zoetis Inc. will post 2.37 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a $0.105 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.59%. Zoetis’s payout ratio is currently 22.11%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.